trametinib,dabrafenib
novartis
['trametinib', 'dabrafenib']
combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the braf v600e mutation. presented at aacr 2023. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.